Comparison of the predictive value of Padua and the IMPEDE assessment scores for venous thromboembolism in patients with newly diagnosed multiple myeloma: A single institution experience.
- Author:
Li Juan FANG
1
;
Xiao Dong YAO
1
;
Min Qiu LU
1
;
Bin CHU
1
;
Lei SHI
1
;
Shao GAO
1
;
Qiu Qing XIANG
1
;
Yu Tong WANG
1
;
Xi LIU
1
;
Yue Hua DING
1
;
Yuan CHEN
1
;
Mengzhen WANG
1
;
Xin ZHAO
1
;
Weikai HU
1
;
Kai SUN
1
;
Li BAO
1
Author Information
- Publication Type:Journal Article
- Keywords: IMPEDE score; Multiple myeloma; Padua score; Venous thromboembolism
- MeSH: Humans; Venous Thromboembolism/etiology*; Multiple Myeloma/diagnosis*; Risk Assessment; Risk Factors; ROC Curve; Retrospective Studies
- From: Chinese Journal of Hematology 2023;44(5):395-400
- CountryChina
- Language:Chinese
- Abstract: Objective: To compare the predictive efficacy of the two thrombosis risk assessment scores (Padua and IMPEDE scores) in venous thromboembolism (VTE) within 6 months in patients with newly diagnosed multiple myeloma (NDMM) in China. Methods: This study reviewed the clinical data of 421 patients with NDMM hospitalized in Beijing Jishuitan Hospital from April 2014 to February 2022. The sensitivity, specificity, accuracy, and Youden index of the two scores were calculated to quantify the thrombus risk assessment of VTE by the Padua and IMPEDE scores. The receiver operating characteristics curves of the two evaluation scores were drawn. Results: The incidence of VTE was 14.73%. The sensitivity, specificity, accuracy, and Youden index of the Padua score were 100%, 0%, 14.7%, and 0% and that of the IMPEDE score was 79%, 44%, 49.2%, and 23%, respectively. The areas under the curve of Padua and IMPEDE risk assessment scores were 0.591 and 0.722, respectively. Conclusion: IMPEDE score is suitable for predicting VTE within 6 months in patients with NDMM.
